Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2013-05-01

Summary

This study is being carried out to see if treatment with ZD1839 (Gefitinib) combined with Arimidex (Anastrozole) has improved efficacy over Arimidex alone in preventing progression of metastatic breast cancer.

• Phase: Phase 2

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Estrogens; Gefitinib; Progesterone